title: Extracorporeal therapies in non-renal disease: treatment of sepsis and the peak concentration hypothesis.
abstract: In the setting of intensive care, patients with acute renal failure often present a clinical picture of the systemic inflammatory response syndrome (SIRS). SIRS can be caused by bacterial stimuli or by non-microbiological stimuli that induce a significant inflammatory response. When this response is exaggerated, the patient experiences multiple organ system failure and a condition of sepsis also defined as a systemic malignant inflammation. This is mostly characterized by an invasion of cytokines and other pro-inflammatory mediators into the systemic circulation where major biological effects take place, including vasopermeabilization, hypotension and shock. At the same time, the monocyte of the septic patient seems to be hyporesponsive to inflammatory stimuli to a certain extent. In this condition, the patient faces a situation of hyperinflammation but at the same time of immunodepression expressing a clinical entity defined as counter anti-inflammatory response syndrome. The general picture of the clinical disorder is therefore better characterized by an immunodysregulation than by a simple pro- or anti-inflammatory disorder. Due to the short half-life of cytokines and other mediators spilled over into the circulation, it is extremely difficult to approach the problem at the right moment with the right pharmacological agent. For these reasons, the peak concentration hypothesis suggests that continuous renal replacement therapies, due to their continuity and unspecific capacity of removal, might be beneficial in cutting the peaks of the concentrations of both pro- and anti-inflammatory mediators, restoring a situation of immunohomeostasis. Thus the patient may benefit from a lesser degree of immunodysregulation and he/she may restore a close-to-normal capacity of response to exogenous stimuli.
authors.affiliation: Department of Nephrology, St. Bortolo Hospital, Vicenza, Italy. cronco@goldnet.it
authors.forename: Claudio
authors.initials: C
authors.lastname: Ronco
authors.forename: Monica
authors.initials: M
authors.lastname: Bonello
authors.forename: Valeria
authors.initials: V
authors.lastname: Bordoni
authors.forename: Zaccaria
authors.initials: Z
authors.lastname: Ricci
authors.forename: Vincenzo
authors.initials: V
authors.lastname: D'Intini
authors.forename: Rinaldo
authors.initials: R
authors.lastname: Bellomo
authors.forename: Nathan W
authors.initials: NW
authors.lastname: Levin
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic; D015331:Cohort Studies; D016207:Cytokines / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000097:blood / Q000502:physiology; D019446:Endotoxemia / Q000150:complications / Q000628:therapy; D006801:Humans; D018836:Inflammation Mediators / Q000037:antagonists & inhibitors / Q000097:blood / Q000502:physiology; D007422:Intestines / Q000098:blood supply; D007511:Ischemia / Q000150:complications; D009994:Osmolar Concentration; D010195:Pancreatitis / Q000150:complications; D006435:Renal Dialysis; D013552:Swine; D018746:Systemic Inflammatory Response Syndrome / Q000097:blood / Q000209:etiology / Q000276:immunology / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D016207:Cytokines; D018836:Inflammation Mediators